Back to discover
Disease

Anaplastic large cell lymphoma

Late-stage therapeutic development
Also known as ALCL, CD30 Positive anaplastic large cell lymphoma, CD30 positive anaplastic large cell lymphoma, Ki-1 lymphoma+5 more

ALCL, CD30 Positive anaplastic large cell lymphoma, CD30 positive anaplastic large cell lymphoma, Ki-1 lymphoma, Ki-1 positive anaplastic large cell lymphoma, Ki-1+ ALCL, Ki-1+ anaplastic large cell lymphoma, primary systemic ALCL, sACL.

21
Clinical trials
10
Associated genes
3
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q3 2027.
Upcoming Milestones
Clinical Milestones9View all 9
Results expected 4
Recently completed 4
Other updates 1
+1 more in the activity timeline below
Activity timeline9

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Crizotinibapproved

Approval — Xalkori as monotherapy is indicated for: The first line treatment of adults with anaplas… (2012)

Clinical trials

12 sponsors · 0 new · 2 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
21
All trials
6
Active
3
Late-stage
6
Completed
Recently completed

A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)

Phase 2 · Completed · University of Milano Bicocca

Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Phase 1/2 · Completed · M.D. Anderson Cancer Center

Phase II Study of Vinorelbine for Children with Recurrent Anaplastic Large Cell Lymphoma

Phase 2 · Completed · Children's Cancer Group, China

A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)

Phase 2 · Completed · National Cancer Institute (NCI)

Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")

Phase 2 · Completed · European Organisation for Research and Treatment of Cancer - EORTC

A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Phase 3 · Completed · Millennium Pharmaceuticals, Inc.

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2012emaApproval — Crizotinib· Xalkori as monotherapy is indicated for: The first line treatment of adults with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) The treatment of adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) The treatment of adults with ROS1 positive advanced non small cell lung cancer (NSCLC) The treatment of paediatric patients (age 1 to <18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) The treatment of paediatric patients (age 1 to <18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK) positive unresectable inflammatory myofibroblastic tumour (IMT) source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

10 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

TNFRSF80.53ALK0.51NPM10.41TPM30.38TFG0.38ATIC0.37MSN0.28JUNB0.11SLAMF80.08PPID0.07

Disease biology

3 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Tumor necrosis factor receptor superfamily member 8via TNFRSF80.53ALK tyrosine kinase receptorvia ALK0.51Nucleophosminvia NPM10.41

Reference

Authoritative identity, definition & identifiers.

Synonyms

ALCL, CD30 Positive anaplastic large cell lymphoma, CD30 positive anaplastic large cell lymphoma, Ki-1 lymphoma, Ki-1 positive anaplastic large cell lymphoma, Ki-1+ ALCL, Ki-1+ anaplastic large cell lymphoma, primary systemic ALCL, sACL

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.